I. Establish a biologic specimen repository (of tumor tissue, tissue arrays, lymphoblastoid
cell lines, host DNA, tumor and host RNA, serum, and plasma) and database linked to clinical
features and outcomes from well-characterized cohorts of children and young adults with
II. Provide specimens from diagnosis, early response evaluation, completion of chemotherapy
and radiotherapy, long-term follow up, and relapse to study prognostic factors for early
response, relapse, long-term outcomes, and identification of new biological targets for
OUTLINE: This is a multicenter study.
Patients enrolled on Hodgkin's lymphoma (HL) therapeutic clinical trials undergo collection
of tumor tissue samples at baseline and at relapse or disease progression. Serum and
anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of
course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after
diagnosis, and at relapse or disease progression.
Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval
clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral
blood samples at relapse or disease progression.
Patients enrolled more than 1 year after completion of treatment undergo collection of tumor
specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation.